Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00054977 | Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors | PHASE1 | COMPLETED | 40 | — | — | Feb 1, 2003 | Sep 1, 2006 | Mar 12, 2012 | 4 | United States |
| Name | Type | Description |
|---|---|---|
| GM-CT-01 | DRUG | IV infusion over 30 minutes of 6 Dosages escalated from 30 to 280 mg/m2, given for 4 consecutive days in a 28 days cycle. |
| 5-fluorouracil | DRUG | IV infusion over 30 minutes at Dosage of 500 mg/m2, given in-combination with GM-CT-01, for 4 consecutive days in a 28 days cycle. |
Inclusion Criteria: * The subject is able to give informed consent to participate in this trial (including all procedures and follow-up visits). * The subject is male or female at least 18 years of age. * The subject has a documented histologic or cytologic recurrent or metastatic solid tumor that ...